| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions.
|
1995
|
2.20
|
|
2
|
Brain iron and ferritin in Parkinson's and Alzheimer's diseases.
|
1990
|
1.27
|
|
3
|
Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.
|
1992
|
1.23
|
|
4
|
Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type.
|
1993
|
1.15
|
|
5
|
The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease.
|
1993
|
1.14
|
|
6
|
Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).
|
1992
|
1.11
|
|
7
|
Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease.
|
1993
|
1.05
|
|
8
|
Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.
|
1992
|
1.04
|
|
9
|
Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.
|
1990
|
1.03
|
|
10
|
Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors.
|
1993
|
1.01
|
|
11
|
Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders?
|
1994
|
1.01
|
|
12
|
Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease.
|
1991
|
1.00
|
|
13
|
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
|
1989
|
0.99
|
|
14
|
Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis.
|
1993
|
0.98
|
|
15
|
The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra.
|
1989
|
0.98
|
|
16
|
The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
|
1994
|
0.98
|
|
17
|
Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters.
|
1993
|
0.96
|
|
18
|
Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex.
|
1990
|
0.96
|
|
19
|
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.
|
1994
|
0.95
|
|
20
|
Mitochondrial enzyme deficiencies in Down's syndrome.
|
1994
|
0.94
|
|
21
|
Total and paramagnetic metals in human substantia nigra and its neuromelanin.
|
1993
|
0.91
|
|
22
|
Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases.
|
1991
|
0.91
|
|
23
|
Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
|
1992
|
0.90
|
|
24
|
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
|
1993
|
0.90
|
|
25
|
Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease.
|
1994
|
0.90
|
|
26
|
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
|
1991
|
0.89
|
|
27
|
Effects of botulinum neurotoxin and Lambert-Eaton myasthenic syndrome IgG at mouse nerve terminals.
|
1989
|
0.89
|
|
28
|
Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
|
1993
|
0.89
|
|
29
|
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides.
|
1995
|
0.88
|
|
30
|
Cognitive and memory deficits in untreated Parkinson's disease and amyotrophic lateral sclerosis patients: a comparative study.
|
1993
|
0.88
|
|
31
|
Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease.
|
1995
|
0.86
|
|
32
|
Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease.
|
1990
|
0.86
|
|
33
|
Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
|
1995
|
0.85
|
|
34
|
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
|
1991
|
0.85
|
|
35
|
Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease.
|
1993
|
0.85
|
|
36
|
Quantification of motor deficit in Parkinson's disease with a motor performance test series.
|
1992
|
0.85
|
|
37
|
Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease.
|
1993
|
0.84
|
|
38
|
Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum.
|
1992
|
0.84
|
|
39
|
Lamotrigine--antiparkinsonian activity by blockade of glutamate release?
|
1993
|
0.84
|
|
40
|
Extrapyramidal signs in Alzheimer's disease: a 3-year follow-up study.
|
1992
|
0.84
|
|
41
|
Intranigral injected iron progressively reduces striatal dopamine metabolism.
|
1994
|
0.83
|
|
42
|
MPTP-induced behavioural and biochemical deficits: a parametric analysis.
|
1994
|
0.83
|
|
43
|
Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type.
|
1992
|
0.83
|
|
44
|
Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
|
1990
|
0.83
|
|
45
|
The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.
|
1994
|
0.82
|
|
46
|
Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid.
|
1993
|
0.82
|
|
47
|
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
|
1991
|
0.82
|
|
48
|
Circadian secretion pattern of melatonin in Parkinson's disease.
|
1991
|
0.82
|
|
49
|
PET imaging of neocortical monoaminergic terminals in Parkinson's disease.
|
1995
|
0.82
|
|
50
|
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
|
1990
|
0.82
|